公开(公告)号：EP2118087B1

公开(公告)日：2012-03-28

申请号：EP08729174.6

申请日：2008-02-06

申请人： Novartis AG

发明人： PECCHI, Sabina ,  NI, Zhi-jie ,  BURGER, Matthew ,  WAGMAN, Allan ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  NG, Simon ,  PFISTER, Keith, B. ,  SMITH, Aaron ,  ZHANG, Yanchen ,  MERRITT, Hanne ,  VOLIVA, Charles

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/5377 ,  A61P35/00

CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14

摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.

公开(公告)号：EP2118087A1

公开(公告)日：2009-11-18

申请号：EP08729174.6

申请日：2008-02-06

申请人： Novartis AG

发明人： PECCHI, Sabina ,  NI, Zhi-jie ,  BURGER, Matthew ,  WAGMAN, Allan ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  NG, Simon ,  PFISTER, Keith, B. ,  SMITH, Aaron ,  ZHANG, Yanchen ,  MERRITT, Hanne ,  VOLIVA, Charles

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/5377 ,  A61P35/00

CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14

摘要： Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.

公开(公告)号：EP1989201A1

公开(公告)日：2008-11-12

申请号：EP07757005.9

申请日：2007-02-14

申请人： NOVARTIS AG

发明人： NI, Zhi-jie ,  PECCHI, Sabina ,  BURGER, Matthew ,  HAN, Wooseok ,  SMITH, Aaron ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  IWANOWICZ, Ed ,  HENDRICKSON, Tom ,  KNAPP, Mark ,  MERRITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  LEGRAND, Darren Mark ,  BRUCE, Ian ,  DALE, James ,  LAN, Jiong ,  LEVINE, Barry ,  COSTALES, Abran ,  LIU, Jie ,  PICK, Teresa ,  MENEZES, Daniel

IPC分类号： C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/428 ,  A61P35/00

CPC分类号： C07D487/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

摘要： Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.